<DOC>
	<DOCNO>NCT01466270</DOCNO>
	<brief_summary>RATIONALE : Donepezil hydrochloride may help lessen cognitive dysfunction cause chemotherapy . PURPOSE : This phase II trial study donepezil hydrochloride treat cognitive dysfunction chemotherapy female breast cancer survivor .</brief_summary>
	<brief_title>Study Donepezil Female Breast Cancer Survivors With Cognitive Dysfunction</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility conduct randomize placebo-controlled clinical trial cognitive symptom female breast cancer survivor . Secondary - Estimate variability clinical outcome ( FACT-Cognition Perceived Cognitive Impairment subscale , neurocognitive battery , FACIT-Fatigue , FACT Cog Total Score , PROMIS Fatigue , Epworth Sleepiness Scale , Beck Depression Inventory , Beck Anxiety Inventory , RAND Short Form-36 ) . - Estimate within patient correlation time clinical outcome . - Obtain preliminary estimate effect donepezil primary secondary outcome variable . - Correlate report fatigue , sleep disturbance , mood measure cognitive symptom neurocognitive test performance . - Document severity cognitive symptom functional impairment female breast cancer survivor enroll pilot study . - Correlate cognitive symptom cognitive test performance . - Document toxicity associate donepezil hydrochloride use . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord menopausal status ( pre- v peri-/post-menopausal ) time since end chemotherapy ( 12-36 month v 36.01-60 month ) . Arm I : Patients receive donepezil hydrochloride orally ( PO ) daily ( QD ) . Arm II : Patients receive placebo PO QD . In arm treatment continue 24 week . Patients complete entire battery neurocognitive test questionnaire ( FACT-Cognition Perceived Cognitive Impairment subscale , neurocognitive battery , FACIT-Fatigue , FACT Cog Total Score , PROMIS Fatigue , Epworth Sleepiness Scale , Beck Depression Inventory , Beck Anxiety Inventory , RAND Short Form-36 ) baseline ( pre-treatment ) , 24 week ( end medication ) , 36 week ( end wash-out ) . After completion therapy , patient follow 12 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>INCLUSION CRITERIA : Adults &gt; 18 year old . Female history invasive breast cancer Must complete adjuvant chemotherapy 1 5 year prior registration Received least 4 cycle cytotoxic chemotherapy Documentation prior chemotherapy Patients receive ongoing hormonal therapy breast cancer must hormonal agent least 3 month prior study registration continue duration study ( 9 month ) Karnofsky Performance Status must &gt; 60 ECOG 02 . Use psychotropic medication ( antidepressant , anxiolytic , sleep aid , narcotic ) permit . Patient ask list take within last 3 day recent medication sheet . Patients must able give informed consent participate study , include sign consent form . Selfreported cognitive disruption ( FACTCog Version 3 Perceived Cognitive Impairments subscore &lt; 63 ) Negative serum pregnancy test within 10 day prior registration woman childbearing potential . EXCLUSION CRITERIA : Evidence suspect recurrent metastatic disease History dementia , Alzheimer 's disease , multiinfarct dementia CVA ( history transient ischemic attack ( TIA allow ) Current use donepezil , galantamine , rivastigmine , tacrine , memantine , methylphenidate , dextroamphetamine , specific cognition enhance drugs.are allow . For patient used medication must use within 4 week prior registration . Patients may currently take Ketoconazole Quinidine Hypersensitivity donepezil . Use investigational medication within last 30 day . Prior brain metastasis Traumatic brain injury , multiple sclerosis recent myocardial infarction History schizophrenia , psychosis substance abuse Untreated current severe depression . ( Currently treat depression permit treatment stable . ) Acute severe fatigue , chronic fatigue syndrome fibromyalgia . History hepatic renal dysfunction disease Pregnant woman exclude study . The effect donepezil develop human fetus recommend therapeutic dose unknown . For reason donepezil know teratogenic , woman childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform study physician immediately . It unknown whether donepezil excrete breast milk , reason woman currently breastfeed eligible study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>fatigue</keyword>
	<keyword>sleep disorder</keyword>
	<keyword>depression</keyword>
	<keyword>anxiety disorder</keyword>
	<keyword>cognitive/functional effect</keyword>
	<keyword>breast cancer</keyword>
	<keyword>cancer survivor</keyword>
</DOC>